Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.3% and a total average
Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability
Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $20 From $22